SteelPeak Wealth LLC Has $72,000 Position in Cardiff Oncology, Inc. $CRDF

SteelPeak Wealth LLC lifted its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 23.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,800 shares of the company’s stock after buying an additional 4,300 shares during the period. SteelPeak Wealth LLC’s holdings in Cardiff Oncology were worth $72,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Baader Bank Aktiengesellschaft bought a new stake in Cardiff Oncology during the second quarter worth about $32,000. Ledgewood Wealth Advisors LLC bought a new stake in Cardiff Oncology in the first quarter valued at approximately $35,000. Belpointe Asset Management LLC bought a new stake in Cardiff Oncology in the first quarter valued at approximately $37,000. Castleview Partners LLC bought a new stake in Cardiff Oncology in the first quarter valued at approximately $45,000. Finally, Brighton Jones LLC acquired a new position in shares of Cardiff Oncology in the first quarter valued at approximately $52,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 30th. The shares were bought at an average price of $2.45 per share, for a total transaction of $36,750.00. Following the transaction, the director directly owned 1,345,676 shares in the company, valued at approximately $3,296,906.20. This trade represents a 1.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.70% of the stock is currently owned by insiders.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock opened at $2.38 on Friday. The company has a market cap of $158.34 million, a P/E ratio of -2.74 and a beta of 1.62. The business has a 50-day moving average price of $2.21 and a two-hundred day moving average price of $2.89. Cardiff Oncology, Inc. has a 1-year low of $1.90 and a 1-year high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Equities research analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on CRDF shares. Jefferies Financial Group started coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They issued a “hold” rating and a $3.50 target price on the stock. LADENBURG THALM/SH SH began coverage on Cardiff Oncology in a report on Tuesday, July 8th. They issued a “buy” rating and a $19.00 target price on the stock. HC Wainwright reduced their target price on Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday. Finally, William Blair reaffirmed an “outperform” rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.63.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.